Hematologic Oncology

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

The FDA has approved oral azacitidine for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy who are not able to complete intensive curative therapy.

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

Venetoclax plus azacitidine led to a statistically significant prolongation of overall survival with a higher incidence of remission in treatment-naïve older patients with acute myeloid leukemia.

Biomarkers predictive of risk in hematopoietic stem cell transplantation–associated thrombotic microangiopathy have undergone a recent evolution, with several new markers under exploration and many efforts focused on making current markers more precise and accurate to strengthen diagnostic criteria.

Catherine Lai, MD, MPH, discusses ​the potential benefits of venetoclax in acute myeloid leukemia.

Rafael F. Duarte, MD, PhD, FRCP, presents 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Eleni Gavriilaki, MD, PhD, discusses the rationale for the lectin pathway as a therapeutic target in hematopoietic stem cell transplantation–associated thrombotic microangiopathy.

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

Sandy Wong, MD, discusses the ANDROMEDA trial, the need for further investigation of venetoclax, and research with anti-amyloid fibril drugs in light chain amyloidosis.

Meletios A. Dimopoulos, MD, discusses the goal of the phase 3 ASPEN trial in Waldenström macroglobulinemia.

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Lori A. Leslie discusses several key studies evaluating emerging approaches in the relapsed/refractory follicular lymphoma paradigm.

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Investigators are evaluating the efficacy of enzastaurin, a PCKß inhibitor, in combination with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with high-risk DGM1–positive diffuse large B-cell lymphoma.

The novel investigational STAMP inhibitor asciminib significantly improved the major molecular response rate compared with bosutinib at 24 weeks in adult patients with Philadelphia chromosome–positive, chronic-phase chronic myeloid leukemia who received prior treatment with 2 or more TKIs.

Enasidenib in combination with best supportive care failed to significantly improve overall survival in patients with relapsed/refractory acute myeloid leukemia whose tumors harbor an IDH2 mutation.

Tafasitamab has been added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

The novel phospholipid-drug conjugate CLR 131 induced a 100% overall response rate in patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.